COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

Gynecol Oncol. 2020 Jul;158(1):34-36. doi: 10.1016/j.ygyno.2020.04.703. Epub 2020 Apr 29.

¹ Arizona Oncology (US Oncology Network), Phoenix, AZ, USA; University of Arizona, Phoenix, AZ, USA; Creighton University, Phoenix, AZ, USA. Electronic address: [email protected].
² US Oncology Network, The Woodlands, TX, USA.
³ Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA.
⁴ University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA.
⁵ Duke Cancer Institute, Duke University Health System, Durham, NC, USA.
⁶ Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
⁸ University of Colorado at Denver, Aurora, CO, USA.
⁹ The Ohio State University, James Cancer Center, Columbus, OH, USA.

Abstract

-
The pandemic COVID-19 requires alternative methods and thinking to keep healthcare professionals and patients safe.
-
In COVID-19 hot spots, oral therapies may be viable alternatives to intravenous therapies for treatment of ovarian cancer.
-
Minimizing patient visits to hospitals and cancer clinics may help mitigate the spread of SARS-CoV-2.

Keywords: COVID-19; Oral; Ovarian cancer; SARS-CoV-2; Targeted therapy.